欧洲基因疗法商业化的早期见解。
Early Insights from Commercialization of Gene Therapies in Europe.
作者信息
Touchot Nicolas, Flume Mathias
机构信息
Strategy Consulting, London SW15 2AW, UK.
Kassenärztliche Vereinigung Westfalen Lippe, Dortmund 44141, Germany.
出版信息
Genes (Basel). 2017 Feb 17;8(2):78. doi: 10.3390/genes8020078.
Abstract
After years of research and development, gene therapies are now becoming a commercial reality with several products approved by European regulatory authorities [...].
摘要
经过多年的研发，基因疗法如今正成为商业现实，已有多款产品获得欧洲监管机构批准[...]。
相似文献
1
Early Insights from Commercialization of Gene Therapies in Europe.欧洲基因疗法商业化的早期见解。
Genes (Basel). 2017 Feb 17;8(2):78. doi: 10.3390/genes8020078.
2
Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.英国再生医学产品商业化障碍的行业认知。
Regen Med. 2009 Jul;4(4):549-59. doi: 10.2217/rme.09.21.
3
eHealth in Europe: from Vision to Reality.欧洲的电子健康：从愿景到现实。
Stud Health Technol Inform. 2008;134:163-8.
4
[The regulatory framework for complementary and alternative medicines in Europe].[欧洲补充和替代医学的监管框架]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):771-8. doi: 10.1007/s00103-008-0584-8.
5
Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.将再生医学引入临床：监管与报销的未来
Regen Med. 2015;10(7):897-911. doi: 10.2217/rme.15.51. Epub 2015 Nov 13.
6
European perspective on the costs and cost-effectiveness of cancer therapies.欧洲对癌症治疗成本及成本效益的看法。
J Clin Oncol. 2007 Jan 10;25(2):191-5. doi: 10.1200/JCO.2006.07.8956.
7
[From orthoclone to denosumab, the fast growing market of monoclonal antibodies].[从Orthoclone到地诺单抗，单克隆抗体快速增长的市场]
Med Sci (Paris). 2009 Dec;25(12):1177-82. doi: 10.1051/medsci/200925121177.
8
Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.与美国的实践相比，欧洲的循证审查似乎导致了一些药物价格的降低。
Health Aff (Millwood). 2013 Apr;32(4):762-70. doi: 10.1377/hlthaff.2012.0707.
9
What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?监管机构、支付方和制药行业之间加强早期互动能带来什么好处？
Expert Rev Pharmacoecon Outcomes Res. 2014 Aug;14(4):465-7. doi: 10.1586/14737167.2014.917966. Epub 2014 May 12.
10
[A proposal for reforming psychologists' training in France and in the European Union].[关于法国及欧盟心理学家培训改革的一项提议]
Encephale. 2009 Feb;35(1):18-24. doi: 10.1016/j.encep.2007.11.008. Epub 2008 Apr 2.
引用本文的文献
1
Application of Gene Therapy to Oral Diseases.基因治疗在口腔疾病中的应用。
Pharmaceutics. 2025 Jun 30;17(7):859. doi: 10.3390/pharmaceutics17070859.
2
Beyond Reimbursement Status: Availability of Advanced Therapy Medicinal Products Across the European Union.超越报销状态：欧盟范围内高级治疗用药品的可及性
Ther Innov Regul Sci. 2025 Apr 10. doi: 10.1007/s43441-025-00769-z.
3
Non-Viral Systems Based on PAMAM-Calix-Dendrimers for Regulatory siRNA Delivery into Cancer Cells.基于聚酰胺-胺-杯芳烃树枝状大分子的非病毒系统用于将调控性小干扰RNA递送至癌细胞
Int J Mol Sci. 2024 Nov 24;25(23):12614. doi: 10.3390/ijms252312614.
4
Gene Therapy for Parkinson's Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance.使用中脑发育基因调控多巴胺能神经元维持的帕金森病基因治疗。
Int J Mol Sci. 2024 Nov 18;25(22):12369. doi: 10.3390/ijms252212369.
5
The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene Therapies.生物技术创新的成本：探索细胞和基因疗法的研发成本。
Pharmaceut Med. 2023 Sep;37(5):365-375. doi: 10.1007/s40290-023-00480-0. Epub 2023 Jun 7.
6
Magnetic nanomaterials for wireless thermal and mechanical neuromodulation.用于无线热和机械神经调节的磁性纳米材料。
iScience. 2022 Oct 25;25(11):105401. doi: 10.1016/j.isci.2022.105401. eCollection 2022 Nov 18.
7
AAV vectors: The Rubik's cube of human gene therapy.AAV 载体：人类基因治疗的魔方。
Mol Ther. 2022 Dec 7;30(12):3515-3541. doi: 10.1016/j.ymthe.2022.09.015. Epub 2022 Oct 5.
8
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.个性化医学的融资和报销模式：系统评价以确定当前模式和未来选择。
Appl Health Econ Health Policy. 2022 Jul;20(4):501-524. doi: 10.1007/s40258-021-00714-9. Epub 2022 Apr 4.
9
Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation.造血干细胞的基因编辑：临床转化的希望与障碍
Front Genome Ed. 2021 Mar 31;3:618378. doi: 10.3389/fgeed.2021.618378. eCollection 2021.
10
The Promise and the Hope of Gene Therapy.基因治疗的前景与希望
Front Genome Ed. 2021 Mar 24;3:618346. doi: 10.3389/fgeed.2021.618346. eCollection 2021.
Zotero 插件